StreetAlpha.app
Home › Stocks › AGEN

Agenus Inc (AGEN)

Healthcare
$6.21
▼ −1.27%
LAST CLOSE · NOV 17

Agenus is a Lexington, Massachusetts biotechnology company developing immunotherapies for cancer and autoimmune diseases. It last closed at $6.21 on Nov 17, down 1.27% on the day. The average 12-month price target from 3 analysts is $25.00 (+302.6% from the last close), with a high of $40.00 and a low of $16.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is AGEN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$133.9M
+25.4% vs a year ago
Net income
$30.8M
23.0% margin
EPS (diluted)
$0.23
Free cash flow
−$103.9M
−77.5% margin
Valuation
Market cap
$281.0M
45.2M shares
P/E
27.0
Price over 12 month EPS
Price to sales
2.1
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$66.9M
At Sep 30
Debt
$29.8M
At Sep 30
Shareholder equity
−$105.4M
Shares outstanding
45.2M
At Nov 3
CEOGaro H. Armen
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $295.7M$295.7MFY2021FY2022: $98.0M$98.0MFY2022FY2023: $156.3M$156.3MFY2023FY2024: $103.5M$103.5MFY2024FY2025: $114.2M$114.2MFY2025

From AGEN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on AGEN in the past 90 days
Average 12-month target
$25.00
▲ 302.6% upside

Based on 3 analysts who set a price target on AGEN in the past 90 days. The average target is $25.00, with a high of $40.00 and a low of $16.00, compared with the last close of $6.21.

Low $16.00Avg $25.00High $40.00
Blue marker: last close $6.21
Highest target$40.00
Average target$25.00
Lowest target$16.00
Latest rating changes
B. Riley SecuritiesTarget raised
Nov 9Buy$14 → $16
Chardan CapitalMaintained
Oct 5Buy$40
Rodman & RenshawInitiated
Sep 28Buy$19
Chardan CapitalInitiated
Sep 18Buy$40
HC Wainwright & Co.Target lowered
Aug 11Buy$30 → $25
DateFirmActionRatingPrice target
Nov 9B. Riley SecuritiesTarget raisedBuy$14 → $16
Oct 5Chardan CapitalMaintainedBuy$40
Sep 28Rodman & RenshawInitiatedBuy$19
Sep 18Chardan CapitalInitiatedBuy$40
Aug 11HC Wainwright & Co.Target loweredBuy$30 → $25
Loading…

Technical Analysis

AGEN · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 8% below its 20 day and 18% below its 50 day average. It is 17% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 41). The nearest support is the Pivot at $6.18, and the nearest resistance the Pivot R1 at $6.40.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 7.8%/day
Key levels
$10.3152 week high+66.0%
$7.3050 day average+17.6%
$7.30Swing high (Oct 29)+17.6%
$6.84100 day average+10.1%
$6.7220 day average+8.2%
$6.40Pivot R1+3.1%
$6.21Last close
$6.18Pivot−0.5%
$6.11Swing low (Oct 27)−1.6%
$5.99Pivot S1−3.5%
$5.14200 day average−17.2%
$2.7152 week low−56.4%
Indicators
RSI (14)40.65Middle of its rangeNeutral
MACD-0.17Below its signal lineBearish
Stochastic22.3Middle of its rangeNeutral
ADX (14)16.1No clear trend
Williams %R-85.2Oversold below −80, overbought above −20Oversold
CCI (20)-124.0Oversold below −100, overbought above 100Oversold
Rate of change−6.9%Change over 10 sessionsBearish
ATR (14)$0.49Typical daily range, 7.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for AGEN

What happened before

See how AGEN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AGEN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AGEN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AGEN in the last 90 days.

Loading…

See today’s whale options flow across the market →

AGEN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲76 buying vs 44 selling
  • ▲Held by funds +26.6 pts
  • ▲Funds holding +21
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding125104+20.2%
In funds' top 1000–
Held by funds58.1%31.5%+26.6 pts
New / increased41 / 3532 / 32+18.8%
Reduced / sold out24 / 2018 / 15+33.3%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AGEN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AGEN is in one of them and how their past AGEN trades turned out.

AGEN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AGEN in an article yet. Here's the latest on the wider market.

About Agenus

Agenus is a biotechnology company based in Lexington, Massachusetts. It is developing immunotherapy product candidates aimed at cancer and autoimmune diseases. Its target customers are physicians and patients, and sales depend heavily on coverage and reimbursement from insurers and government healthcare programs. Its product candidates have not yet received marketing approval, and it competes with established treatments such as chemotherapy and radiation therapy.

Headquarters
Lexington, MA
Founded
1994